Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Never forget, translational experience based on mAbs is pretty established, so odds may be in favour...
Questions is, what and when comes the next update...
They are due for:
I-Cell Covid Vaccine preclinical data
Covi-Trap Fc-ACE2 protein trap
Smartpharm update
MabPharm update
NK Cell approach
Celularity
Pain program
CarT and DarT potential licensing
And there is much more which may drop at any time...
Pretty explosive.
Shortly they hopefully will give some details to preclinical studies...
If positive, watch out...
If approved in Singapore, they will get access to many Asian countries....
Arct Starr technology may need only 1/10 of mRNA amount compared to other players.
Truly disruptive.
Tc
Could they risk to increase concentration of Bri in the next SOM trial, at least in the more problematic low Gy subgroup?
Hey Daubers
Where do you have this from?
10q or similar?
Thx
Ho do you know it is mid-December ?
Tc
Hi Nerby
That is also my last hope scenario...
Was really wondering about the 3 Milestone package they signed with Aspire at that time.
Good luck to all
Pix
I wonder how FDA will sort out the
„Control“ issue.
The slightest indication of full or partial acceptance of historic control (as per FDA review in 2017) and the stock will sky rocket.
At this point, market anticipates a new trial (per SPA) and another year of delay.
And no credit to the first trial,
Which showed already efficay....
Market Cap should be at least at 150 Mio USD, based on above...imo
Tc
It will
Decided to step in.
Now long 30000.
Top product, poor management.
But have the feeling FDA will help.
Xena
What do you think about Ampe?
Did you hear yesterdays TC?
CEO believes FDA may change perception, when discussing trial design acceptance from 2017 (instead of 2016 minutes)
He believes, this mess is mostly caused by restructuring within the agency, thereby loosing the knowledge base in this case...
Tc Pix
Topline could come pretty fast...
My feeling is Keith has left the company...
Will touch 0.25
Right, may be a bit to optimistic...
Actually, there was a bit of misleading by Keith, as he suggested an imminent deal and and 510K filing....but there seems only to be imminent dilution yet.
A bit disappointing but this is pink land...
Again, submitted yet or not?
Q to Keith:
Has at least the Musculo Skeletal Pain
510K already been filed????
Tc
Finally it is starting.
I mean at least for UK....
Why no PR on Total Pathways???
Can anybody tell me, why the charting
has stopped on Biel here at Ihub???
Pls advise.
I use the actipatch for treating edema of a ski thumb (teared tendon)
Works great.
Yes
But no results posted...
Hi
Have the results of the following study already been PRd?
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain (PSWT)
If yes, pls provide link.
Thx
Will we get straight P Top line results?
Anyone???
We only know:
„Once the full dataset has been unblinded, received and reviewed, the Company will release the results.“
Can happen at any time...
Or the opposite.
We simply do not know.
Interestingly they have added about 10 patients to the study....
Hint, that they have internally seen the interim????
I have a good feeling about performance of P.
Dont know why, but the way IPIX is dealing with Newsflow lately makes me optimistic.
I still see lot of value in IPIX compounds. That is why i added some shares during this downturn.
Long 102k
Johnson & Johnson scraps phase 3 antibiotic program acquired in $30B Actelion takeover
Interesting:
Nature Cell and Biostar Stem Cell Research Institute Begin World’s First Stem Cell-Based Regenerative Treatment for Alzheimer's Disease in Japan
Autologous adipose tissue-derived mesenchymal stem cells applied to Alzheimer’s patients for the first time
World’s first intravenous injection of stem cells over 10 applications developed by Biostar Stem Cell Research Institute and Dr. Jeong-Chan Ra
Treatment can be applied to mild-to-moderate Alzheimer’s patients; around 80 patients booked for the treatment until May
April 13, 2018 10:12 AM Eastern Daylight Time
SEOUL, South Korea--(BUSINESS WIRE)--South Korea’s Biostar Stem Cell Research Institute (CEO: Jeong-Chan Ra), jointly operated by Nature Cell and Rbio, today announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12.
Earlier in March, Trinity Clinic Fukuoka received approval from the Kyushu Certified Special Committee for Regenerative Medicine for the safety and effectiveness in applying regenerative medicine to Alzheimer’s patients, based on the Act on the Safety of Regenerative Medicine in Japan. The evaluation results were delivered to the Kyushu branch office of Japan’s Ministry of Health, Labor and Welfare (MHLW), and the treatment was officially approved by the Ministry on April 11.
Trinity Clinic Fukuoka started the first stem cell treatment to three Korean Alzheimer’s patients, who were each administered with 200 million cells over two hours. They will receive treatment every two weeks, for a total of 10 treatments.
The stem cell therapy of Alzheimer's disease is to administer autologous adipose tissue-derived mesenchymal stem cells intravenously. This is a novel approach to treating Alzheimer’s disease, using unique stem cell technologies that have been developed over more than 13 years. The treatment involves a number of patented technologies, such as methods for producing stem cells of a size suitable for intravascular administration, culture medium compositions for regenerating stem cells, and compositions for enhancing storage stability of serum-containing stem cells. Dr. Jeong-Chan Ra has been testing intravenous injections in his own body since 2008 to evaluate the safety of this process. Moreover, the safety of intravenous infusion has been established in clinical trials in the United States. Published clinical studies show that multiple injections are unlikely to cause cancer in humans.
Unlike the existing treatment for Alzheimer’s disease that only slows the progression of the illness, stem cell therapy is expected to be a fundamental cure for the disease. Dr. Ra’s research team tested animals that have Alzheimer's disease and proved the effectiveness of the stem cell treatment of Alzheimer’s disease as well as the prevention of Alzheimer’s disease. Dr. Ra’s study was also published in the international journal Plos-One in 2012, and the treatment is known to perform multiple functions including anti-inflammation, cerebral vascular regeneration, and brain cell protection and regeneration.
Stem cell therapy can be applied to mild-to-moderate Alzheimer’s patients who are aged 65 or older. Patients with early-stage Alzheimer’s disease who are 55 years or older can also receive the stem cell treatment if their family members or guardians agree to the treatment. However, pregnant women and those with serious diabetes or cardiac failure cannot receive the treatment.
Chang-hee Yang, CEO of Trinity Clinic Fukuoka, said, “It is a great honor to become the first medical institute to use stem cell technology in treating Alzheimer’s patients. Reservations for around 80 patients have already been received for treatment until May, and additional inquiries are steadily being received about reservations for the therapy. As the world is seeing accelerated growth in aging populations and a drastic increase in Alzheimer’s patients, the need for treating Alzheimer’s patients can be met at Trinity Clinic Fukuoka.”
Dr. Jeong-Chan Ra, who developed the stem cell treatment for Alzheimer’s disease, explained his vision, saying, “This is the first step in our project to overcome Alzheimer’s, which was launched with our commitment to conquer this disease. With the start of stem cell treatment, Biostar will support Alzheimer’s patients from all over the world – including Japan, Korea, China, and the U.S., starting in Japan – to restore their memory and ultimately their humanity.”
Residents of Japan who are suffering from Alzheimer’s can receive treatment by directly contacting Trinity Clinic Fukuoka. Residents in South Korea, the United States and other countries can inquire with Biostar Korea for a treatment reservation.
Nature Cell
Nature Cell (KOSDAQ: 007390) is a high-tech bio enterprise, a leader of stem cell business, stem cell drugs and treatment technology development, and stem cell culture medium cosmetics. Nature Cell also manufactures and sells health supplements and foods that help adults improve their memory. Furthermore, Nature Cell is a member of the stem cell network Biostar, along with Rbio, GDFI Braincell Laboratory, Stem Cell Research Institute, Stemcell Life Foundation, Bethesda Hospital, R-Japan and Medicorp, which are entities committed to stem cell research for treating incurable diseases. More information about Nature Cell can be found at www.naturecell.co.kr.
Biostar Stem Cell Research Institute
Biostar Stem Cell Research Institute is jointly run by Nature Cell and RBio, the adult-derived stem cells research firm. The institute has cutting edge technologies and equipment for stem cell separation, cultivation and storage, and strives to develop technologies for commercialization of JointStem, an autologous stem cell-based medicine for degenerative arthritis patients; AstroStem, treatment of spinal injury patients and Alzheimer's disease; VascoStem, a candidate for a new drug to treat Burger’s disease, which causes ischaemic necrosis, and the Parry Romberg disease, which causes anti-facial atrophy. More details about Biostar Stem Cell Research Institute can be found at http://ko.stemcellbio.com.
Contacts
Nature Cell
Sanghoon Song
shsong@naturecell.co.kr
or
Access Communication & Consulting Co.
Soyeon Kim, +82-10-9256-6285
sykim@accesspr.co.kr
or
Sehui An, +82-10-7749-3298
shan@accesspr.co.kr
NATURE CELL
KOE:007390
#Hashtags
#stemcell #Alzheimers #medicalnews #stemcells #dementia #stemcellresearch
Release Versions
English EON: Enhanced Online News
Log InSign Up
More from Business Wire
BlogAppsUK/IrelandDeutschlandFranceHong KongItalyJapanEON: Enhanced Online NewsTradeshownews.com
Contact UsUK Tax StrategyPrivacy StatementTerms of Use© 2018 Business Wire, Inc.
The subject was monitored over a period of 12 months, and demonstrated no safety or adverse events.
1 Patient report....
Not good for statistics,....
If prolonged linear or non linear dose response, we should see better efficacy.
If already plateaued, not.
This is what the trial is to determine...
Tc
Anything around 30% PASI 75
I just have a good feeling about our progress.
Now its a matter of days or few weeks.
Valuation may change quickly...